Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
It is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.
Full description
The purpose of the study is to identify a dose (or doses) of BLZ945, that measurably decrease(s) TSPO binding in the brain of participants with ALS, to evaluate the safety and tolerability of BLZ945 in participants with ALS at these doses and dosing regimens, and safety related effects on ECM accumulation. In Cohort 5, TSPO PET will be performed in a dedicated cohort (PET sub-study) while the remainder of Cohort 5 participants will undergo CSF-based biomarker analyses.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
28 participants in 8 patient groups
Loading...
Central trial contact
Novartis Pharmaceuticals; Novartis Pharmaceuticals
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal